BioWorld® - Medical Device Daily
27.11.2012 • Views
Share Embed Flag

BioWorld® - Medical Device Daily

BioWorld® - Medical Device Daily

BioWorld® - Medical Device Daily

SHOW MORE
SHOW LESS
ePAPER READ
DOWNLOAD ePAPER
medicaldevicedaily.com

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

START NOW

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information<br />

Altus Pharmaceuticals Inc.<br />

125 Sidney Street<br />

Cambridge MA 02139-4807, US<br />

Phone: (617) 299-2900; Fax: (617) 299-2999<br />

Toll-free phone: (888) ALT-CLEC<br />

Web: www.altus.com; E-mail: info@altus.com<br />

KEY PERSONNEL: John Richard; Chairman<br />

Sheldon Berkle; President and CEO<br />

Jonathan Lieber; VP, CFO and Treasurer<br />

Alexey L. Margolin, Ph.D.; Sr. VP, Research and Preclinical Development<br />

and CSO<br />

Burkhard Blank, M.D.; Sr. VP, Medicine, Regulatory Affairs and Project<br />

Management<br />

Renato Fuchs; Sr. VP, Manufacturing and Technical Operations<br />

Don G. Burstyn, Ph.D.; VP, Regulatory Affairs and Quality Assurance<br />

Alan Kimura, M.D., Ph.D.; VP, Clinical Development and <strong>Medical</strong> Affairs<br />

Robert Gallotto; VP, Commercial Development and Alliance Management<br />

Lauren Sabella; VP, Commercial Development<br />

John M. Sorvillo, Ph.D.; VP, Business Development<br />

EMPLOYEES: 25 employees, 8 Ph.D.s<br />

HISTORY: Founded in December 1992<br />

FACILITIES: 3,000 sq. ft. fully equipped facility<br />

STOCK-FINANCIAL HISTORY: NASDAQ--ALTU<br />

IPO--7M shares at $15/share, $105M (1/06)<br />

Revenue $8.288M (YE 05) compared to $4.230M (YE 04)<br />

Net loss (YE 05) compared to (YE 04)<br />

Loss per share (YE 05) compared to (YE<br />

04)<br />

Average shares outstanding 1.719M (YE 05) compared to 1.704M (YE 04)<br />

Total assets $40.584M (YE 05) compared to $62.824M (YE 04)<br />

PRIVATE PLACEMENTS: Raised $35M in private financing (10/01)<br />

Raised $15M in second closing of Series B financing (12/01)<br />

Raised $51M in Series C financing (5/04)<br />

SUBSIDIARY OF: Vertex Pharmaceuticals Inc. (see separate entry)<br />

PRINCIPAL INVESTORS: BankInvest<br />

China Development Industrial Bank (CDIB)<br />

Clariden Bank<br />

CMEA Ventures<br />

Hotung International Co. Ltd.<br />

Nomura International<br />

Palladin Group<br />

U.S. Venture Partners<br />

Vertex Pharmaceuticals<br />

Warburg Pincus<br />

FINANCIAL INFORMATION: Awarded $500K grant to develop catalysts to neutralize nerve agents using<br />

Cross-Linked Enzyme Crystal technology (1/97)<br />

Received $51M in Series C financing led by Warburg Pincus and including<br />

U.S. Venture Partners, Nomura Phase4 Ventures, BankInvest, CMEA<br />

Ventures and Clariden Bank (5/04)<br />

BUSINESS STRATEGY: Develop a series of products jointly with potential users while retaining broad<br />

rights to distribute to entire market<br />

AGREEMENTS: Name Products Content of Agreement Date<br />

Dr. Falk Pharma TheraCLEC development and 2/03<br />

GmbH<br />

commercialization<br />

agreement<br />

Copyright ©2006 AHC Media ® 34

logo

products

Resources

Company

Terms of service
Privacy policy
Cookie policy
Cookie settings
Imprint
Change language
Made with love in Switzerland
© 2024 Yumpu.com all rights reserved

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!